CASI Pharmaceuticals, Inc.

CASIFSEC EDGAR

Pharmaceutical Preparations(E9)CIK: 1962738

Concept	FY2024	FY2023	FY2022
Revenue from Contract with Customer, Excluding Assessed Tax	$38.0M	$30.0M	$15.0M
Cost of Goods and Services Sold	$15.8M	$12.6M	$9.5M
Gross Profit	$27.3M	$17.6M	$5.6M
Research and Development Expense	$16.0M	—	—
Operating Income (Loss)	-$34.0M	-$41.5M	-$52.8M
Interest Expense	—	—	$3.1K
Other Nonoperating Income (Expense)	$44.0K	$558.0K	$82.0K
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	-$37.4M	-$35.8M	-$47.5M
Income Tax Expense (Benefit)	$2.0M	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$41.0M	-$36.7M	-$48.3M
Earnings Per Share, Basic

Concept	FY2024	FY2023	FY2022
Assets	$75.3M	$96.2M	$138.3M
Assets, Current	$59.3M	$73.4M	$62.0M
Cash and Cash Equivalents, at Carrying Value	$17.1M	$47.1M	$38.7M
Accounts Receivable, after Allowance for Credit Loss, Current	$9.6M	$13.0M	$9.8M
Inventory, Net	$15.9M	$6.1M	$1.9M
Liabilities	$51.1M	$29.3M	$30.3M
Liabilities, Current	$16.7M	$17.0M	$13.2M
Long-term Debt, Excluding Current Maturities	$18.9M	$18.9M	—
Accounts Payable, Current	$4.4M	$3.3M	$2.2M
Stockholders' Equity Attributable to Parent	$84.5M	$81.5M	$73.0M

Concept	FY2024	FY2023	FY2022
Net Cash Provided by (Used in) Operating Activities	-$21.1M	-$26.8M	-$25.9M
Net Cash Provided by (Used in) Investing Activities	$31.2M	-$20.7M	-$20.7M
Net Cash Provided by (Used in) Financing Activities	-$3.3M	$29.6M	$47.2M
Payments to Acquire Property, Plant, and Equipment	$5.6M	$8.9M	$1.5M
Payments for Repurchase of Common Stock	$3.3M	$3.3M	$3.3M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)